Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: Effects on myocardial salvage  by Marfella, Raffaele et al.
International Journal of Cardiology 168 (2013) 3954–3962
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdPeri-procedural tight glycemic control during early percutaneous coronary
intervention up-regulates endothelial progenitor cell level and differentiation during
acute ST-elevation myocardial infarction: Effects on myocardial salvage☆☆
Raffaele Marfella a,⁎, Maria Rosaria Rizzo a, Mario Siniscalchi b, Pasquale Paolisso a, Michelangela Barbieri a,
Celestino Sardu a, Antonella Savinelli a, Nicola Angelico c, Salvatore Del Gaudio d, Nicolino Esposito c,
Pier Francesco Rambaldi e, Nunzia D'Onofrio e, Luigi Mansi e, Ciro Mauro b,
Giuseppe Paolisso a, Maria Luisa Balestrieri f
a Department of Geriatrics and Metabolic Diseases Second University of Naples, Italy
b Department of Cardiology, Hospital Cardarelli, Naples, Italy
c Evalgelico Hospital Villa Betania, Naples, Italy
d Department of Internal Medicine Pineta Grande Hospital, Caserta, Italy
e Department of Nuclear Medicine Division, Second University of Naples, Italy
f Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, ItalyAbbreviations: AMI, acute myocardial infarction; CGC
EPCs, endothelial progenitor cells; IGC, intensive glycemic
mononuclear cells; MS, myocardial salvage; PCI, percu
SIRT1, silent information regulator 1; STEMI, ST-segment e
☆☆ ClinicalTrials.com identiﬁer: NCT01016509.
⁎ Corresponding author at: Department of Geriatrics
University of Naples, Piazza Miraglia, 2, 80138 Naples,
fax: +39 081 5665303.
E-mail address: raffaele.marfella@unina2.it (R. Mar
0167-5273 © 2013 The Authors. Published by Elsevier
http://dx.doi.org/10.1016/j.ijcard.2013.06.053a b s t r a c ta r t i c l e i n f oArticle history:
Received 9 May 2013
Accepted 29 June 2013





Background: We examined the effects of peri-procedural intensive glycemic control during early percutaneous
coronary intervention (PCI) on the number and differentiation of endothelial progenitor cells (EPCs) and myo-
cardial salvage (MS) in hyperglycemic patients with ﬁrst ST-elevation myocardial infarction (STEMI).
Methods and results:We conducted a randomized, prospective, open label study on 194 patients with STEMI un-
dergoing PCI: 88 normoglycemic patients (glucose b 140 mg/dl) served as the control group. Hyperglycemic pa-
tients (glucose ≥ 140 mg/dl) were randomized to intensive glycemic control (IGC) for almost 24 h after PCI
(n = 54; 80–140 mg/dl) or conventional glycemic control (CGC, n = 52; 180–200 mg/dl). EPC number, differ-
entiation, and SIRT1expressionwere assessed immediately before, 24 h, 7, 30 and 180 days after PCI. The primary
end point of the study was salvage index, measured as the proportion of initial perfusion defect (acute
technetium-99m sestamibi scintigraphy, performed 5 to 7 days after STEMI) and myocardium salvaged by ther-
apy (6 months after STEMI). Hyperglycemic patients had lower EPC number and differentiation and lower SIRT1
levels than normoglycemic patients (P b 0.01). After the insulin infusion, mean plasma glucose during peri-
procedural period was greater in CGC group than in IGC group (P b 0.001). The EPC number, their capability to
differentiate, and SIRT1 levels were signiﬁcantly higher in IGC group than in CGC, peaking after 24 h (P b 0.01).
In the IGC group, the salvage index was greater than in patients treated with CGC (P b 0.001).
Conclusions: Optimal peri-procedural glycemic control, by increasing EPC number and their capability to differ-
entiate, may improve the myocardial salvage.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license., conventional glycemic control;
control; PBMC, peripheral blood
taneous coronary intervention;
levation myocardial infarction.
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A positive association between hyperglycemia at the time of the
event and subsequent mortality from acute myocardial infarction
(AMI) has been reported [1]. Moreover, a recent study suggests that
stress hyperglycemia affectsmyocardial salvage, indicating that thema-
nipulation of glucose levels could be a potential therapeutic target for
salvaging ischemic damage [2]. Although the mechanisms underlying
this association are not fully understood, evidence that the use of insulin
to lower glucose concentrations decreasesmortality in diabetic patients
who have AMI [3] suggests that hyperglycemia is not simply an epiphe-
nomenon of a stress response. Consequently, hyperglycemia at the time-NC-ND license.
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poor outcome [4].
A growing body of evidence suggests that circulating endothelial
progenitor cells (EPCs) are mobilized endogenously in response to
tissue ischemia and, thereby, augment neovascularization of ischemic
tissues [5,6]. In patients with AMI, EPCs, deﬁned as CD34+/KDR+ pro-
genitor cells, are increased in peripheral blood and are rapidly recruited
tomyocardiummediating a protective effect on vascular healing and is-
chemic preconditioning and salvaging the ischemic myocardium in the
acute phase of AMI [7]. The impaired abundance and activation of EPCs
at the time of myocardial infarction are known to occur in diabetic pa-
tients [8], although the mechanisms by which the diabetic status im-
pairs EPCs mobilization and subsequent domiciliation to infarcted
tissue are poorly understood. Our recentﬁndings show that the number
of EPCs was signiﬁcantly higher in patients with good glycemic control
than those with poor glycemic control [9], and when more glucose was
added to EPC cultures in vitro, viability and proliferation decreased
whereas apoptosis increased [9]. However, the role of hyperglycemia
on dynamics of EPC mobilization in the acute coronary syndrome, in
human, has not been investigated before. It has been suggested that
hyperglycemia-induced overproduction of oxidative stress, through
the acceleration of EPC senescence, can explain the EPC impairments
observed in diabetes [10]. Indeed, in vitro studies demonstrated that
in EPCs the levels and activity of mammalian silent information regula-
tor 1 (SIRT1), implicated in the prevention of stress-induced senescence
endothelial dysfunction [11], are downregulated during short-term ex-
posure to high-glucose concentrations. Whether EPC levels are de-
creased and contribute to the poor outcome of AMI in hyperglycemic
patients is not known, as well as it is unclear whether strict glycemic
control, in the context of PCI, improves both the EPC mobilization and
function. On this basis, our study evaluated whether the EPC number
and activity during ST-segment elevation myocardial infarction (STEMI)
is inﬂuenced by hyperglycemia as well as whether peri-procedural
tight glycemic control during angioplasty revascularization for STEMI is
capable of increasing EPC number and activity and potentially contrib-
uting to improved recovery from myocardial damage. Myocardial sal-
vage is the principal mechanism by which patients with AMI beneﬁt
from reperfusion therapies [12]. It can reliably be quantiﬁed by 99mTc
sestamibi imaging [12]. Repeated myocardial imaging with 99mTc-
sestamibi performed early after symptom onset and 180 days after pri-
mary reperfusion treatment allows reliable assessment of the area at
risk, ﬁnal infarct size, and salvage index or the proportion of area at
risk that is salvaged by reperfusion therapy [12]. However, no informa-
tion is available on the effects of intensive glycemic control on myocar-
dial salvage in patientswith AMI.We undertook this study to investigate
the value of myocardial salvage in patients with AMI treatedwith inten-
sive glycemic control and the possible relationships with the functional
characteristics of mobilized EPCs in the peripheral circulation.2. Methods
2.1. Patients
This was a randomized, prospective, open label study to compare two therapeutic
strategies after PCI with stent: intensive glycemic control vs. conventional glycemic con-
trol in patients with hyperglycemia and STEMI. In the simple randomization process we
used computer generated random list. According to the recent statement by the American
Heart Association, hyperglycemia was deﬁned as an admission plasma glucose level of
N140 mg/dl [4]. The control group included patients with a normal plasma glucose
(b140 mg/dl). We analyzed the consecutive patients presenting with ﬁrst STEMI admit-
ted to the Department of Cardiology of the Cardarelli Hospital in Naples, Pineta Grande
Hospital, Caserta and Evalgelico Hospital Villa Betania, Naples (Italy) from December
2009 to December 2012. Inclusion criteria included: age of 18 years or greater, presenta-
tion to the cardiac catheterization laboratory for PCI in the setting ofﬁrst STEMI. All STEMI
patients were referred to the cardiac catheterization laboratory within 12 h of presenta-
tion. Patientswith left ventricular ejection fraction less than 25%, with previousmyocardi-
al infarction or previous PCI or/and coronary by-pass grafting were excluded. Moreover,
patients with restenosis at 6 month follow-up were also excluded from the evaluations.
The following patients were referred for urgent invasive diagnostics with the intentionof performing PCI: symptom duration of 12 h or less and ST-segment elevation of
0.1 mV or greater in at least 2 contiguous leads (≥0.2 mV in V1–V3) or presumed
new-onset left bundle-branch block. Theywere included in the study after they gavewrit-
ten informed consent. Patients who experienced unsuccessful ﬁbrinolytic therapy were
also referred for PCI. Routine analyses were obtained on admission before coronary angi-
ography and before full medical therapy were started. A group of 15 healthy volunteers
(33 ± 8 years) recruited at the clinic centers were used as healthy subjects for the evalu-
ations of EPC number, differentiation, and SIRT1 normal values. The investigation con-
forms with the principles outlined in the Declaration of Helsinki for the use of human
tissue or subjects. The Institutional Review Board approved the protocol.
2.2. Study protocol
Upon emergency wards admission, all patients were assigned to undergo prompt cor-
onary revascularization. After PCI procedures, hyperglycemic patients were randomly
assigned to intensive glucose control (IGC group) or to conventional glucose control (CGC
group). Operators assigned the patients either in IGC or CGC groups according to a comput-
er generated randomization list. Participants were randomly assigned following simple
randomization procedures (computerized random numbers) to 1 of 2 treatment groups.
In the CGC group, continuous insulin infusion of 50 IU Actrapid HM (Novo-Nordisk) in
50 ml NaCl (0.9% using a Perfusor-FM-pump)was started only when plasma glucose levels
exceeded 200 mg/dl and adjusted to keep plasma glucose between 180 and 200 mg/dl.
When plasma glucose fell b180 mg/dl, insulin infusion was tapered and eventually
stopped. In the IGC group, insulin infusion started when plasma glucose levels exceeded
140 mg/dl and adjusted tomaintain glycemia at 80–140 mg/dl. After the start of insulin in-
fusion protocol, a glycemic controlwas providedevery hour in order to obtain three consec-
utive values that were within the goal range. The infusion lasted until stable glycemic goal
(ICG group: 80–140 mg/dl; CGC group: 180–200 mg/dl) for at least 24 h. After that glyce-
mic goal was maintained for 24 h, the infusion was stopped and subcutaneous insulin was
initiated. Insulin was given as short-acting insulin before meals and long-acting insulin
(insulin glargine) in the evening throughout the period of hospital stay in ICG group. CGC
patients received insulin to achieve a fasting and postprandial blood glucose b200 mg/dl.
After discharge from the hospital, all patients with established diabetes and newly diag-
nosed diabetes were managed and followed for 30 days after PCI, as outpatients, to main-
tain HbA1c level at b7%, blood glucose level of 90–140 mg/dl and post-prandial blood
glucose level of b180 mg/dl. With regard to the full medical therapy, the protocol stated
that the use of concomitant treatment should be as uniform as possible and accorded to
evidence-based international guidelines for STEMI [13].
2.3. Angioplasty procedure
Balloon angioplasty was performed according to standard techniques as recently
described [14]. Dilatation of a stenotic vessel was considered successful if the residual
stenosis of the lumen diameter was less than 30%. The analyses of all angiographic data
were performed by operators who were unaware of the study groups to which the pa-
tients were assigned (Toshiba, Inﬁnix CS-i).
2.4. Scintigraphic evaluation
At 5 to 7 days after STEMI, patients received an intravenous injection of 27 mCi
(1000 MBq) of technetium Tc-99m sestamibi. Single photon emission computed tomog-
raphy was performed within 6 to 8 h after the injection of the radioactive agent. A
follow-up scintigraphy was performed 180 days after the reperfusion therapy. The defect
size was quantiﬁed by using a 50% threshold. All measurements were performed in the
scintigraphic core laboratory by operators who were blinded to treatment allocation.
Quantitative measurements included the initial perfusion defect size (from the initial
scintigram), ﬁnal infarct size (ﬁnal perfusion defect from the follow-up scintigram), de-
gree of myocardial salvage (difference between initial and ﬁnal perfusion defects), and
salvage index (ratio between the degree of myocardial salvage and the initial perfusion
defect size). Paired scintigraphic examinations were needed to obtain salvage index,
which was the primary end point of the study.
2.5. EPC phenotypic characterization and quantiﬁcation
Immediately before PCI and after insulin infusion (24 h) as well as at 7, 30, and
180 days after PCI, peripheral heparinized blood samples (15 ml) were collected in a
fasting condition between7:00 AMand 9:00 AM. EPC number (CD34+/KDR+)was deter-
mined on 100 μL of peripheral heparinized blood samples by ﬂow cytometry analysis
(FACScalibur instrument, BD Biosciences) as described [9,15] within 2 h from blood col-
lection. Antibodies used were CD34 (FITC; Miltenyi Biotech) and KDR (PE; R&D System,
FAB 357P). Collected heparinized blood samples were used to isolate EPC from peripheral
blood mononuclear cells (PBMCs) as previously described [9,15]. Another aliquot of
PBMCs was cultured for 7 days in order to evaluate cell differentiation capacity.
2.6. Evaluation of EPC differentiation
To determine the rate of EPC differentiation after 7 days of cell culture, the expression
of endothelial markers, CD31 and KDR, was evaluated by FACS analysis and confocal
laser-scanning microscopy. FACS analysis was performed as previously described [9,15]
using CD31 (FITC; Biolegend) and KDR (PE; R&D System, FAB 357P) antibodies.
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To determine the functional capacity of circulating EPCs, we cultured MNCs for
7 days to quantify CD31, VEGFR2. MNCs were isolated from 20 mL of peripheral blood
by a density gradient centrifugation method.18 MNCs were cultured on 2% gelatin/
ﬁbronectin-coated dishes at 106 cells/cm2 as described previously [9,15]. Cells were
cultured inM199 supplementedwith 20% fetal bovine serum (Invitrogen/GIBCO, Carlsbad,
Calif), 2 mmol/L glutamine, 100 U/mL penicillin, 100 U/mL streptomycin, and bovine
pituitary extract (Invitrogen/GIBCO). At 7 days of culture, to visualize the upregulation of
endothelial markers, cells were ﬁxed, incubated with anti-human antibodies, and stained
with biotinylated anti-mouse or rabbit Ig antibodies, and with FITC and Texas red-avidin
with DAPI counterstaining, and observed using an epiﬂuorescencemicroscope (Olympus).
Themarker proteinswere vascular endothelial growth factor receptor (VEGFR2/KDR) (Lab-
Vision), and platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) (Invitrogen).
2.8. Confocal laser-scanning microscopy
Confocal microscope analysis of 3-day and 7-day cultured EPC was performed as de-
scribed [9,15]. Brieﬂy,ﬁxed and permeabilized EPCwas incubatedwith speciﬁc antibodies
against Vimentin (1:1000; Sigma Aldrich) and against SIRT1 (1:500, Abcam) or against
CD31 (1:500, FITC; Biolegend) and KDR (1:500, Cell Signaling). Secondary antibodies
were Alexaﬂuor 633 (1:1000) or Alexaﬂuor 488 (1:1000). Cells were counterstained
with DAPI.Microscopy analyseswere performed using Zeiss LSM510 confocalmicroscope
equipped with a plan-apochromat X 63 (NA 1.4) oil immersion objective [9,15].
2.9. Laboratory analysis
Immediately before PCI and after insulin infusion (24 h) as well as at 7, 30 and
180 days after PCI, glucose levels were measured both in plasma and blood. The eval-
uations of blood glucose were provided by glucometers “plasma equivalent”. All the
glucometers used showed satisfactory imprecision and were reliable in reporting plasma-
equivalent glucose concentrations. The differences between glucose measured in the lab
(plasma glucose) and glucose measured with meter were less than 5%. HbA1c levels
were assayed with the high-performance liquid chromatography (HPLC). The determina-
tions were performed by operators who were unaware of the study groups to which the
patients were assigned.
2.10. Study end point
The primary end point of the study was the salvage index. The secondary outcome
measure was EPC number and capability to differentiate in the early phase of STEMI.
The original primary endpoint was in-stent restenosis, but, during analysis, we noted
that in patients without restenosis the infarct size was lower in normoglycemic than
hyperglycemic patients. Therefore we decided to adopt as co-primary endpoint the sal-
vage index in patients without restenosis.Fig. 1. Flow diagram of the progress through the p3. Statistical analysis
All calculations were performed using the computer program
SigmaStat 3.5. Continuous variables were expressed as the mean ±
SD and were analyzed for signiﬁcant differences using the two-tailed
Student t test, when comparing IGC and CGC groups. Categorical vari-
ables were expressed as percentages and were analyzed for signiﬁcant
differences using Pearson's chi-square test, two-tailed Fisher exact test
as appropriate. To determine the independent predictors of myocardial
salvage, all variableswith a p value b0.2 (included the amount of insulin
infused) were included in a multiple stepwise regression analysis. The
sample size had a power of 40% estimated according to a global effect
size of 25% with type I error of 0.05. Therefore a sample size of 50 pa-
tients per group was necessary.
4. Results
4.1. Baseline characteristics of the patients on admission at emergency
wards
A total of 402 patients with suspected STEMI were transferred to or
admitted directly to PCI center. Flow diagram of a multicentre trial was
reported in Fig. 1. Brieﬂy, hundred-two patients were excluded because
primary PCI was not performed, 79 patients were excluded due to a
delay in the treatment greater than 24 h, 12 patients were unwilling
to provide clinical information, and 8 subjects had their plasma samples
unavailable for biochemical analysis. During the ﬁrst 30 days after
PCI, 7 patients died. Therefore, 194 patients completed the study: 88
normoglycemic patients (glucose b 140 mg/dl) (control group) and
106 hyperglycemic patients (glucose ≥ 140 mg/dl). Hyperglycemic pa-
tients were randomized to intensive glycemic control (IGC) for almost
24 h after PCI (n = 54; glucose 80–140 mg/dl) or conventional glyce-
mic control (CGC, n = 52; glucose 180–200 mg/dl). On admission,
despite the similar electrocardiogram alteration on admission in the
3 groups of patients, troponin I levels were signiﬁcantly higher in pa-
tients with hyperglycemia than in normoglycemic patients (Table 1)
(P b 0.005). There was no correlation between the time from thehases of a parallel randomized trial of groups.
Table 1
Clinical characteristics, angiographic and procedural data.
Baseline 6 months
Control group IGC group CGC group Control group IGC group CGC group
N 88 54 52 86 52 49
Mean age (years) 66 ± 11 66 ± 13 65 ± 12 66 ± 13 65 ± 9 66 ± 14
Sex (M/F) 48/40 29/25 27/25 46/40 28/24 25/24
BMI (kg/m2) 28 ± 2.9 27 ± 3.1 28 ± 2.0 28 ± 2.6 27 ± 3.7 28 ± 2.4
Waist-to-hip ratio 0.73 ± 00.8 0.72 ± 0.09 0.71 ± 0.08 0.72 ± 00.6 0.72 ± 0.07 0.71 ± 0.09
Systolic blood pressure (mmHg) 130 ± 14 129 ± 13 128 ± 14 130 ± 11 129 ± 12 128 ± 14
Diastolic blood pressure (mmHg) 79 ± 10 77 ± 6 78 ± 8 79 ± 12 77 ± 8 78 ± 9
Heart rate (bpm) 85 ± 15 84 ± 18 85 ± 16 84 ± 12 84 ± 19 85 ± 15
Killip class, n (%)
I 79 (90) 48 (89) 47 (90) / / /
II 6 (7) 4 (8) 4 (7) / / /
III 3 (3) 2 (3) 1 (3) / / /
Risk factors
Diabetes, n (%) 9 (10) 20 (37)⁎ 20 (38)⁎ 8 (9) 51 (98)⁎ 49 (100)⁎
Hypertension, n (%) 51 (58) 31 (57) 29 (55) 50 (57) 31 (60) 27 (55)
Hyperlipidemia, n (%) 22 (25) 13 (25) 14 (27) 24 (25) 12 (23) 12 (25)
Obesity, n (%) 30 (34) 20 (37) 19 (37) 30 (34) 20 (38) 19 (39)
Cigarette smoking, n (%) 20 (23) 11 (21) 10 (19) 2 (2) 2 (4) 1 (2)
Active treatments
β-Blockers, n (%) 11 (12) 8 (14) 7 (14) 63 (72)† 38 (74)† 36 (74)†
ACE inhibitors, n (%) 19 (22) 12 (23) 10 (20) 37 (42)† 22 (43)† 22 (45)†
Angiotensin receptor blockers, n (%) 27 (31) 18 (33) 18 (34) 28 (32) 18 (34) 17 (35)
Statins, n (%) 40 (46) 26 (48) 25 (49) 84 (96)† 51 (98)† 48 (99)†
Thiazide diuretic, n (%) 8 (9) 5 (9) 5(10) 8 (9) 5 (10) 5 (10)
Insulin, n (%) 4 (5) 10 (19)⁎ 9 (18)⁎ 2 (2) 15 (29)⁎† 17 (35)⁎†
Oral antidiabetic, n (%) 5 (6) 10 (19)⁎ 11 (21)⁎ 7 (8) 45 (86)⁎† 44 (89)⁎†
Aspirin, n (%) 66 (75) 51 (94)⁎ 49 (95)⁎ 83 (95)† 49 (96) 48 (98)
Clopidogrel, n (%) 83 (94) 51 (94) 50 (96) 83 (95) 50 (97) 47 (97)
Fibrinolitic therapy before PCI, n (%) 23 (26) 14 (26) 15 (28) / / /
Laboratory analyses
Fasting blood glucose, mg/dl 102 ± 14 233 ± 32⁎ 230 ± 34⁎ 97 ± 9 143 ± 20⁎† 139 ± 22⁎†
Post-prandial blood glucose, mg/dl / / / 131 ± 12 177 ± 21⁎ 175 ± 26⁎
HbA1c, % 5.1 ± 0.1 8.7 ± 3.1 8.8 ± 3.0 5.2 ± 0.1 7.3 ± 1.2 7.1 ± 1.6
HbA1c (mmol/mol) 32 ± 2 72 ± 10⁎ 73 ± 9⁎ 33 ± 3 56 ± 10⁎† 54 ± 11⁎†
LDL-cholesterol (mg/dl) 112 ± 20 117 ± 13 118 ± 14 102 ± 11 113 ± 12 110 ± 11
HDL-cholesterol (mg/dl) 42 ± 12 39 ± 16 40 ± 14 43 ± 10 41 ± 11 41 ± 16
Triglycerides (mg/dl) 159 ± 44 174 ± 84 178 ± 90 161 ± 46 166 ± 32 168 ± 27
Creatinine (mg/dl) 1.0 ± 0.6 1.1 ± 0.6 1.0 ± 0.8 1.0 ± 0.5 1.1 ± 0.7 1.0 ± 0.7
Troponin (μg/L) 8.9 ± 2.4 13.4 ± 3.8⁎ 13.1 ± 3.6⁎ / / /
Procedural data
Symptom onset to enrollment, h 1.8 ± 0.4 1.8 ± 0.3 1.9 ± 0.5 / / /
Symptom onset to PCI, h 2.6 ± 0.9 2.4 ± 0.7 2.4 ± 0.9 / / /
PCI to starting insulin infusion, min / 31 ± 8 30 ± 9 / / /
Stent usage, no. (%)
Drug-eluting 44 (50) 27 (50) 27 (51) / / /
Bare metal 44 (50) 27 (50) 25 (49) / / /
Number of diseased vessels, n (%)
1-VD 53 (60) 33 (61) 32 (62) / / /
2-VD 26 (30) 17 (32) 17 (33) / / /
3-VD 9 (10) 4 (7) 3 (5) / / /
Lesion location, n (%)
LAD 43 (49) 26 (48) 25 (49) / / /
LCx 32 (36) 20 (37) 18 (35) / / /
RCA 19 (22) 11 (21) 12 (23) / / /
Type of lesion, %
A 11 (12) 6 (12) 7 (13) / / /
B 28 (32) 18 (33) 17 (32) / / /
C 49 (56) 30 (55) 29 (56) / / /
PCI procedure
Nominal size of largest balloon, mm 2.87 ± 0.43 2.89 ± 0.42 2.87 ± 0.43 / / /
Balloon to artery ratio 1.15 ± 0.20 1.15 ± 0.18 1.14 ± 0.21 / / /
Total number of inﬂations 3.8 ± 3.1 3.7 ± 3.4 3.7 ± 3.3 / / /
Total duration of inﬂation, s 312 ± 151 310 ± 145 308 ± 144 / / /
Maximum inﬂation pressure, atm 11.6 ± 2.4 11.5 ± 2.3 11.4 ± 2.9 / / /
Quantitative angiographic data
Before angioplasty
Lesion length, mm 13.9 ± 4.9 14.9 ± 6.7 14.7 ± 7.1 / / /
Reference diameter, mm 3.0 ± 0.7 2.8 ± 0.6 2.8 ± 0.4 / / /
MLD, mm 0.6 ± 0.4 0.6 ± 0.6 0.6 ± 0.5 / / /
Percentage stenosis, % 77 ± 12 79 ± 16 78 ± 15 / / /
(continued on next page)
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Table 1 (continued)
Baseline 6 months
Control group IGC group CGC group Control group IGC group CGC group
Quantitative angiographic data
After angioplasty
Reference diameter, mm 2.6 ± 0.6 2.7 ± 0.9 2.7 ± 0.7 / / /
MLD, mm 2.7 ± 0.9 2.6 ± 0.7 2.7 ± 0.6 / / /
Percentage stenosis, % 21 ± 14 23 ± 16 24 ± 12 / / /
Hospital stay (days) 6 ± 2 7 ± 3 7 ± 2 / / /
Scintigraphic evaluation
Initial defect size, % LV (25th–75th percentiles) 20 (16–26) 29 (26–33)⁎ 30 (26–34)⁎ / / /
Final infarct size, % LV (25th–75th percentiles) / / / 10 (7.5–11) 14 (14–16)⁎ 22 (19–24)⁎‡
Myocardial salvage, % LV (25th–75th percentiles) / / / 11 (7–17) 15 (10–19)⁎ 7 (4–12)⁎‡
Salvage index, (25th–75th percentiles) / / / 0.6 (0.4–0.7) 0.5 (0.4–0.6) 0.2 (0.1–0.4)⁎‡
Data are means ± SD, n (%) or median (percentiles). 1-VD indicates single-vessel disease; 2-VD, two-vessel disease; 3-VD, three-vessel disease; LAD, left anterior descending; LCx,
left circumﬂex artery; RCA, right coronary artery; and PCI: percutaneous coronary intervention; MLD, minimal luminar diameter.
⁎ P b 0.05 vs control group.
† P b 0.05 vs baseline.
‡ P b 0.05 vs IGC group.
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P = 1.00). Pretreatment with ﬁbrinolysis was used in 23 patients
(26%) of control group, 14 patients (26%) of IGC group and 15 patients
(28%) of CGC group. The admission plasma glucose level was similar
among IGC and CGC groups (Table 1). There were no differences in
the mean age, BMI, sex distribution, smoking habits, HbA1c, plasma
cholesterol, and triglyceride levels among the 3 groups. The use of
diuretic drugs, angiotensin-converting enzyme inhibitor drugs, beta-
blocker drugs, and calcium channel blocker therapy was similar among
the 3 groups (Table 1). A total of 38% of patients in the CGC group and
37% of patients in the IGC grouphad been previously treated for diabetes,
while the remaining patients were newly diagnosed with diabetes. The
number (Fig. 2) and differentiation of EPCs (Fig. 3) aswell as SIRT1 levels
(Fig. 4) were signiﬁcantly higher in patients with normoglycemia than
in those with in hyperglycemia and healthy subjects. Moreover, there
were no signiﬁcant differences among IGC and CGC groups at baseline.
Angiographic data are summarized in Table 1. The treated lesion types
were similar in the groups (Table 1). The stent type was similar in the
groups (Table 1). Quantitative angiographic analysis is summarized in
Table 1. A mean of 2.3 matched angiographic projections per lesion
was made, than satisfactory quantitative analysis was performed atFig. 2. FACS computed counting of EPCs. (A) Characterization and counting of circulating EPCs b
and gating proﬁle set on the basis of the isotype control sample as used for the quantiﬁcation
*P b 0.01 vs baseline, §p b 0.05 vs CRT, ‡P b 0.05 vs IGC, †P b 0.05 vs HS. HS = healthy sub
conventional glycemic control.the central angiographic laboratory before and after PCI (Table 1). The
reference diameter of the target vessel was similar in the groups. The
mean minimal luminal diameter, and the mean length of the lesion
at baseline were similar in the groups. No signiﬁcant differencewas ob-
served in stent length and stent diameter between the groups (Table 1).
The lesion location, AHA/ACC lesion classiﬁcation, angiographic mea-
surements, and frequency of multi-lesion PCI were similar between
patients with and without diabetes (Table 1). Compared to the hyper-
glycemic patients, the initial perfusion defect was lower in normogly-
cemic group (Table 1). Correlation between the initial perfusion defect
and glucose levels was found (R = 0.69; P b 0.001).
4.2. Effects of glucose-lowering treatments on EPC number and
differentiation, after insulin infusion 1, 7 and 30 and from the PCI in
hyperglycemic patients
There were no difference in themean time between PCI and starting
insulin infusion among the groups. In both groups, the mean time re-
quired to achieve plasma glucose target was 8.4 ± 2.1 h in normogly-
cemic patients, 8.6 ± 2.2 h in IGC and 8.8 ± 2.5 h in CGC group. In
hyperglycemic patients, the insulin infusion duration was 33.9 ± 2.5 hy FACS analysis of the co-expression of CD34/KDR (VEGFR2). (B) Representative FACS plots
of and CD34+KDR+ cells. FL1 = CD34-FITC; FL2 = KDR-PE. Data are mean ± SD, with
jects; CTR = control; HY-IGC = hyperglycaemic-intensive glycemic control; HY-CGC =
Fig. 3. FACS computed counting and confocal laser-scanning microscopy evaluation of EPCs differentiation. (A) FACS analysis of 7-day cultured EPCs (CD31+/KDR+) from
AMI-patients (CTR = control; HY-IGC = hyperglycemic-intensive glycemic control; HY-CGC = conventional glycemic control) and healthy subjects (HS). (B) Representative
FACS plots and gating proﬁle set on the basis of the isotype control sample as used for the quantiﬁcation of and CD31+KDR+ cells. (C) Representative confocal laser-scanning images
of cells co-expressing CD31+ (green) and KDR+ (red). Nuclei were counterstained with DAPI (blue). Data are mean ± SD, with *P b 0.01 vs baseline, §P b 0.05 vs CRT, ‡P b 0.05 vs
IGC, †P b 0.05 vs HS.
Fig. 4. Evaluation of SIRT1 expression in EPCs. Representative confocal images of EPCs from (A) AMI-patients (CTR = control; HY-IGC = hyperglycaemic-intensive glycemic control;
HY-CGC = conventional glycemic control) and (B) Healthy subjects (HS). EPCs were incubated with speciﬁc antibodies against vimentin (green) and SIRT1 (red). Secondary antibodies
were Alexa Fluor 488 andAlexa Fluor 633. (C) Immunoﬂuorescence analysis of SIRT1 (red) and vimentin (green) protein levels. Theﬂuorescence intensity was calculatedwith ImageJ soft-
ware analysis and expressed as arbitrary ﬂuorescence units (AFU). Alexa 488 and Alexa 633 ﬂuorescence emissionswere acquired in multi-trackmode using BP 505–530 and LP650 ﬁlters
respectively. Themean (n = 6) of theunspeciﬁcﬂuorescence of the secondary antibodieswas calculatedwith ImageJ software and subtracted. Data aremean ± SD,with *P b 0.01 vs base-
line, §P b 0.05 vs CRT, ‡P b 0.05 vs IGC, †P b 0.05 vs HS.
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fusedwas 111 ± 29 IU in the IGC patients and 48 ± 7 IU in the CGC pa-
tients. After the insulin infusion period, plasma glucose reduction was
greater in the IGC group than in CGC group (89 ± 29 mg/dl vs 27 ±
22 mg/dl; P b 0.001). Therefore, the mean plasma glucose level during
the peri-procedural period was greater in the CGC group than in IGC
group (CGC, 201 ± 16 mg/dl; IGC, 144 ± 36 mg/dl; P b 0.001). More-
over, the glycemic goal was maintained for 24 h in both groups (ICG,
129 ± 10 mg/dl; CGC, 197 ± 12; P b 0.01). Blood glucose b70 mg/dl
with andwithout symptoms occurred more frequently during the insu-
lin infusion in IGC group (33%) than in CGC group (9%). After insulin in-
fusion, multidose insulin therapy was used in all ICG patients (46 ±
13 IU/day) and in the 21% (n = 25) of CGC patients (44 ± 18 IU/day)
during the whole in-hospital period (ICG, 14 ± 6 days; CGC, 14 ±
7 days). During the hospital stay, blood glucose b70 mg/dl with and
without symptoms occurred more frequently in IGC group (10%) than
in CGC group (3%). Fig. 1 shows the time course of, ECP number
(Fig. 2), differentiation capability (Fig. 3), and EPC SIRT1 protein level
(Fig. 4), were still greater in normoglycemic patients than in healthy
subjects and in IGC and CGC patients. After the insulin infusion period
(24 h) and on day 7 following STEMI, the number and differentiation
of EPCs and SIRT1 levels were higher in the IGC patients compared to
CGC patients (Figs. 2, 3, and 4). Moreover, EPC number and differentia-
tion were signiﬁcantly associated with mean plasma glucose level
during the insulin infusion period, and regression model showed a pos-
itive nonlinear effect (R = 0.31, P b 0.001; R = 0.29, P b 0.001). At
hospital discharge, both fasting and post-prandial blood glucose levels
were higher in CGC group than in ICG group (IGC: fasting, 116 ±
20 mg/dl, post-prandial 168 ± 16 mg/dl; CGC: 147 ± 24 mg/dl, post-
prandial 199 ± 18 mg/dl; P b 0.05 for all). At hospital discharge, all
patients with established type 2 diabetes (IGC, 20 patients; CGC, 20 pa-
tients) and newly diagnosed type 2 diabetes (IGC, 24 patients; CGC, 22
patients) were managed and followed as outpatients for 6 month after
PCI (Table 1). After 30 days from the PCI, both fasting and post-prandial
plasma glucose levels were similar in the two groups (IGC: fasting,
133 ± 28 mg/dl, post-prandial 177 ± 22 mg/dl; CGC: 131 ± 26 mg/dl,
post-prandial 175 ± 31 mg/dl; P = NS for both). After 30 days from
intervention treatment period, there were no differences in the hypo-
glycemic events among the groups (data not shown). After 30 days of
intervention treatment period, the number of EPCs was similar in
normoglycemic and hyperglycemic group without differences among
IGC and CGC groups (Fig. 2). The differentiation of EPC (Fig. 3) and
SIRT1 protein level (Fig. 4) were higher in normoglycemic than hyper-
glycemic groups. However, there were no differences among IGC and
CGC group.
4.3. Effects of glucose-lowering treatments on the myocardial salvage,
after 180 days from the PCI
There was no difference in HbA1c (P = NS) at 6 months among the
patients from both hyperglycemic groups. There was no difference in
hypoglycemic and medical out-patient treatment therapy during the
follow-up among the groups (IGC, 14%; CGC, 15%). After 180 days
from the PCI, both fasting and post-prandial plasma glucose levels
were similar in the two groups (IGC: fasting, 143 ± 20 mg/dl, post-
prandial 177 ± 21 mg/dl; CGC: 139 ± 22 mg/dl, post-prandial 175 ±
26 mg/dl; P = NS for both). After 180 days of intervention treatment
period, the number of EPCs was similar in normoglycemic and hyper-
glycemic group without differences among IGC and CGC groups
(Fig. 2). The differentiation of EPC (Fig. 3) and SIRT1 protein expression
levels (Fig. 4)was higher in normoglycemic thanhyperglycemic groups,
however, therewere no differences among IGC and CGC group.Myocar-
dial salvage index was compared between normoglycemic and hyper-
glycemic patients (Table 1, Fig. 5). The myocardial salvage index was
similar in normoglycemic and in IGC patients. In the hyperglycemic
group, the salvage index was signiﬁcantly greater among IGC patientsas compared with the CGC patients (Table 1, Fig. 4). Moreover, EPC
number and differentiation changes during the ﬁrst 24 h after STEMI
were signiﬁcantly associatedwithmyocardial salvage index, and regres-
sion model showed a positive nonlinear effect (R = 0.41, P b 0.001;
R = 0.49, P b 0.001). In addition, using the data pertaining to the entire
study population, we built a multiple linear regression model with sal-
vage index as a dependent variable and age, sex, diabetes, HbA1c,
mean plasma glucose level during the insulin infusion period and the
other cardiovascular risk factors, infarct localization, proportion of
ST-elevation infarction, time-to admission, door-to-reperfusion treat-
ment time. After adjustment in the multivariate model mean plasma
glucose level during the insulin infusion period remained an indepen-
dent predictor Of the salvage index (P b 0.02). By 6 months, mortality
was 2.2% (n = 2) in the control group, 3.7% (n = 2) in the IGC group
and 5.7% (n = 3) in the CGC group.
5. Discussion
Themain message of the present study, on different goal for glucose
control in patients with hyperglycemia submitted to PCI for STEMI, is
that peri-procedural tight glycemic control signiﬁcantly increased the
area of myocardial salvage accompanied with a reduction of the ische-
mic area and greater recovery of LV function at 6 months after stenting.
Tight glycemic control, for at least 24 h, is associated with a doubled in-
crease in myocardial salvage in the IGC patients compared to that of the
CGC group, despite both the intensive and conventionally treated
groups returned to their usual glucose lowering management at the
end of the active phase of the study. These data, consistent with those
of previous studies, support the proposition that stress hyperglycemia
was associated with impaired myocardial salvage in patients on admis-
sion for AMI [2]. Furthermore, we found that the tight control of
peri-procedural plasma glucose levels were associated with improved
myocardial salvage independently from HbA1c levels. These observa-
tions suggest that the acute metabolic milieu at the time of the PCI is
more signiﬁcant than chronic glycemic control in setting the stage for
myocardial salvage. A support for the potential beneﬁt of early optimal
glycemic control during PCI to improvemyocardial salvage at 6 months
may also be derived from clinical studies suggesting that the injurious
effects of exposure to high glucose levels persist for years after better
treatment, a phenomenon typically referred to a hyperglycemic memo-
ry [16]. Of particular interest were the ﬁndings from the Diabetes Con-
trol and Complications Trial and its follow-up observational study, the
Epidemiology of Diabetes Intervention and Complications trial where
the term “hyperglycemic memory” was introduced [17,18]. This term
was used to explain a phenomenon where the long-term vascular
beneﬁts of a previous period of good glycemic control persisted despite
a return to usual, often worse metabolic control. In this context, exper-
imental evidence indicates that short-term memory of hyperglycemic
conditions is associatedwith long-term changes in chromatinmodiﬁca-
tions [19]. Indeed, short-term exposure to high-glucose concentration
showed a sustained decrease in the number and the functional proper-
ties of EPCs in diabetic patients [9]. In the process of myocardial regen-
eration, bonemarrow-derived and peripheral tissue-derived progenitor
cells appear to be able to regenerate a myocardium by enhancing the
neovascularization [20,21]. These pro-angiogenic mechanisms may
allow EPCs to positively contribute to the regeneration of an ischemic
myocardium after reperfusion therapy. Moreover, recent studies have
found that the magnitude of circulating EPCs appearing as CD34+/
KDR+ after MI may predict the clinical outcome and prognosis [21,22].
Regarding EPC function, we ﬁrst measured the effect of thigh glycemic
control on the abundance and differentiation capability of EPCs of
hyperglycemic patients with AMI and compared them with clinical
outcome parameters. In accordance with the literature [5–7], we have
shown that there is a considerable increase of EPC number early after
AMI in normoglycemic patients. However, we demonstrate that the in-
crease of EPC levels is affected in hyperglycemic patients early after
Fig. 5.Myocardial salvage between the groups. (A) Salvage index in the control group, intensive glycemic control group (IGC) and conventional glycemic control group (CGC). In all box
plots, the top of the box represents the 75th percentile, the bottom of the box represents the 25th percentile, and the line in the middle represents the 50th percentile. The whiskers (the
lines that extend out the top and bottom of the box) represent the highest and lowest values that are not outliers or extreme values. Outliers (values that are between 1.5 and 3 times the
interquartile range) and extreme values (values that aremore than 3 times the interquartile range) are represented by circles beyond thewhiskers. *P b 0.05 vs control group. ‡P b 0.05 vs
IGC group. (B), Representative cases of technetium Tc-99m sestamibi scintigraphy from each group at baseline (5 to 7 days after STEMI) and at follow-up (180 days after STEMI).
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tion and the function of EPC hyperglycemic patients, the increased
level and differentiation of EPCs after insulin infusion were greater in
IGC than in CGC patients. These differences among IGC and CGC patients
continued until seven days after STEMI. Since a rapid and considerable
increase of circulating EPCs, which occurs during acute ischemia, corre-
lates with healing and functional recovery of injured areas [6], it has
been hypothesized that pharmacologic interventions leading to glyce-
mic control may inﬂuence the recovery of myocardial function and
other yet-unrecognized mechanisms through the amelioration of the
EPC number and functionality. These effects may result in an increased
myocardial salvage. As for mechanisms behind this association, we
evidenced that during STEMI a downregulation of SIRT1 levels is ob-
served in hyperglycemic patients compared to normoglycemic patients.
Several cellular processes including insulin secretion, cell cycle, and ap-
optosis are imperatively regulated by a family of mediators called
sirtuins. Among sirtuins, ﬁrst knownmammalian sirtuin, SIRT1, is a pos-
itive regulator of EPC mobilization and differentiation [23,24,15]. SIRT1actions may affect cellular pathways involved in aging and metabolic
diseases. In particular, evidence suggests an important role for SIRT1in
shear stress-induced EPC differentiation [25]. In this framework, our
data suggest that hyperglycemia-induced downregulation of SIRT1
may play a pivotal role in the reduced number and function of EPC in
hyperglycemic patients during STEMI. Accordingly, previous study
evidences that SIRT1 protein level and activity are decreased in type 2
diabetic patients with poor glycemic control with respect to patients
with good glycemic control [9]. Since SIRT1 has been shown to play a
pivotal role in the differentiation of EPCs, detection of low levels of
SIRT1 in CGC patients but not in IGCpatients is strongly suggestive of re-
duced EPC number and function and, thus, of impairedmyocardial func-
tion linked to a decreased availability of EPC function during STEMI.
According to this construct, we evidenced that tight glycemic control
(129 ± 10 mg/dl) in the immediate PCI procedure period, for almost
24 h, was associated with the up-regulation of SIRT1. Tight glycemic
controlwas associatedwith higher levels of both SIRT1 and EPCnumber
in IGC patients compared to CGC patients. In particular, we proved
3962 R. Marfella et al. / International Journal of Cardiology 168 (2013) 3954–3962evidence of the increase of EPC number and differentiation capacity, as
well as SIRT1 protein level, only after insulin infusion and not during
follow-up. In this context, the increased EPC number and functionality,
i.e., differentiation capability and SIRT1 protein level, evoked by tight
glycemic control in the peri-procedural period may play a critical role
in contributing to an increased myocardial salvage at 6 months. But,
above all, it is very intriguing that our study parameters of EPC number
and differentiation assessed after insulin infusion, similarly to mean
glycemic values, were correlated with myocardial salvage index at
180 days after PCI. Therefore, these ﬁndings strongly support the hy-
pothesis that an increase of EPC level and capability of differentiation
could take part to a favorable effect of peri-procedural tight glycemic
control during early percutaneous coronary intervention onmyocardial
salvage in patients with acute ST-elevation myocardial infarction.
6. Study limitation
The limited number of patients as well as the short period of
observation are the limitations of our study. Therefore, further studies
involving a larger number of patients will be needed to conﬁrm our
data.
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